The global RNA-Targeted Small Molecule Drugs market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global RNA-Targeted Small Molecule Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global RNA-Targeted Small Molecule Drugs market size and forecasts, in consumption value ($ Million), 2020-2031
Global RNA-Targeted Small Molecule Drugs market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global RNA-Targeted Small Molecule Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global RNA-Targeted Small Molecule Drugs market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for RNA-Targeted Small Molecule Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global RNA-Targeted Small Molecule Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, PTC Therapeutics, Biogen, Accent Therapeutics, Anima Biotech, Arrakis Pharmaceuticals, Epics Therapeutics, Expansion Therapeutics, Gotham Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
RNA-Targeted Small Molecule Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
mRNA Translation Regulation
RNA Splicing Modification
Direct RNA Targeting
Indirect RNA Targeting - Epitranscriptomics
麻豆原创 segment by Application
SMA
Oncology
Lung Fibrosis
Huntington's Disease
Others
麻豆原创 segment by players, this report covers
Roche
Novartis
PTC Therapeutics
Biogen
Accent Therapeutics
Anima Biotech
Arrakis Pharmaceuticals
Epics Therapeutics
Expansion Therapeutics
Gotham Therapeutics
H3 Biomedicine
Ribometrix
Skyhawk Therapeutics
STORM Therapeutics
Twentyeight-Seven Therapeutics
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe RNA-Targeted Small Molecule Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of RNA-Targeted Small Molecule Drugs, with revenue, gross margin, and global market share of RNA-Targeted Small Molecule Drugs from 2020 to 2025.
Chapter 3, the RNA-Targeted Small Molecule Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and RNA-Targeted Small Molecule Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of RNA-Targeted Small Molecule Drugs.
Chapter 13, to describe RNA-Targeted Small Molecule Drugs research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of RNA-Targeted Small Molecule Drugs by Type
1.3.1 Overview: Global RNA-Targeted Small Molecule Drugs 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global RNA-Targeted Small Molecule Drugs Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 mRNA Translation Regulation
1.3.4 RNA Splicing Modification
1.3.5 Direct RNA Targeting
1.3.6 Indirect RNA Targeting - Epitranscriptomics
1.4 Global RNA-Targeted Small Molecule Drugs 麻豆原创 by Application
1.4.1 Overview: Global RNA-Targeted Small Molecule Drugs 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 SMA
1.4.3 Oncology
1.4.4 Lung Fibrosis
1.4.5 Huntington's Disease
1.4.6 Others
1.5 Global RNA-Targeted Small Molecule Drugs 麻豆原创 Size & Forecast
1.6 Global RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast by Region
1.6.1 Global RNA-Targeted Small Molecule Drugs 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global RNA-Targeted Small Molecule Drugs 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche RNA-Targeted Small Molecule Drugs Product and Solutions
2.1.4 Roche RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Roche Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis RNA-Targeted Small Molecule Drugs Product and Solutions
2.2.4 Novartis RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Novartis Recent Developments and Future Plans
2.3 PTC Therapeutics
2.3.1 PTC Therapeutics Details
2.3.2 PTC Therapeutics Major Business
2.3.3 PTC Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
2.3.4 PTC Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 PTC Therapeutics Recent Developments and Future Plans
2.4 Biogen
2.4.1 Biogen Details
2.4.2 Biogen Major Business
2.4.3 Biogen RNA-Targeted Small Molecule Drugs Product and Solutions
2.4.4 Biogen RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Biogen Recent Developments and Future Plans
2.5 Accent Therapeutics
2.5.1 Accent Therapeutics Details
2.5.2 Accent Therapeutics Major Business
2.5.3 Accent Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
2.5.4 Accent Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Accent Therapeutics Recent Developments and Future Plans
2.6 Anima Biotech
2.6.1 Anima Biotech Details
2.6.2 Anima Biotech Major Business
2.6.3 Anima Biotech RNA-Targeted Small Molecule Drugs Product and Solutions
2.6.4 Anima Biotech RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Anima Biotech Recent Developments and Future Plans
2.7 Arrakis Pharmaceuticals
2.7.1 Arrakis Pharmaceuticals Details
2.7.2 Arrakis Pharmaceuticals Major Business
2.7.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Product and Solutions
2.7.4 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Arrakis Pharmaceuticals Recent Developments and Future Plans
2.8 Epics Therapeutics
2.8.1 Epics Therapeutics Details
2.8.2 Epics Therapeutics Major Business
2.8.3 Epics Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
2.8.4 Epics Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Epics Therapeutics Recent Developments and Future Plans
2.9 Expansion Therapeutics
2.9.1 Expansion Therapeutics Details
2.9.2 Expansion Therapeutics Major Business
2.9.3 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
2.9.4 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Expansion Therapeutics Recent Developments and Future Plans
2.10 Gotham Therapeutics
2.10.1 Gotham Therapeutics Details
2.10.2 Gotham Therapeutics Major Business
2.10.3 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
2.10.4 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Gotham Therapeutics Recent Developments and Future Plans
2.11 H3 Biomedicine
2.11.1 H3 Biomedicine Details
2.11.2 H3 Biomedicine Major Business
2.11.3 H3 Biomedicine RNA-Targeted Small Molecule Drugs Product and Solutions
2.11.4 H3 Biomedicine RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 H3 Biomedicine Recent Developments and Future Plans
2.12 Ribometrix
2.12.1 Ribometrix Details
2.12.2 Ribometrix Major Business
2.12.3 Ribometrix RNA-Targeted Small Molecule Drugs Product and Solutions
2.12.4 Ribometrix RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Ribometrix Recent Developments and Future Plans
2.13 Skyhawk Therapeutics
2.13.1 Skyhawk Therapeutics Details
2.13.2 Skyhawk Therapeutics Major Business
2.13.3 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
2.13.4 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Skyhawk Therapeutics Recent Developments and Future Plans
2.14 STORM Therapeutics
2.14.1 STORM Therapeutics Details
2.14.2 STORM Therapeutics Major Business
2.14.3 STORM Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
2.14.4 STORM Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 STORM Therapeutics Recent Developments and Future Plans
2.15 Twentyeight-Seven Therapeutics
2.15.1 Twentyeight-Seven Therapeutics Details
2.15.2 Twentyeight-Seven Therapeutics Major Business
2.15.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
2.15.4 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Twentyeight-Seven Therapeutics Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global RNA-Targeted Small Molecule Drugs Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of RNA-Targeted Small Molecule Drugs by Company Revenue
3.2.2 Top 3 RNA-Targeted Small Molecule Drugs Players 麻豆原创 Share in 2024
3.2.3 Top 6 RNA-Targeted Small Molecule Drugs Players 麻豆原创 Share in 2024
3.3 RNA-Targeted Small Molecule Drugs 麻豆原创: Overall Company Footprint Analysis
3.3.1 RNA-Targeted Small Molecule Drugs 麻豆原创: Region Footprint
3.3.2 RNA-Targeted Small Molecule Drugs 麻豆原创: Company Product Type Footprint
3.3.3 RNA-Targeted Small Molecule Drugs 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global RNA-Targeted Small Molecule Drugs Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global RNA-Targeted Small Molecule Drugs 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global RNA-Targeted Small Molecule Drugs Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global RNA-Targeted Small Molecule Drugs 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America RNA-Targeted Small Molecule Drugs Consumption Value by Type (2020-2031)
6.2 North America RNA-Targeted Small Molecule Drugs 麻豆原创 Size by Application (2020-2031)
6.3 North America RNA-Targeted Small Molecule Drugs 麻豆原创 Size by Country
6.3.1 North America RNA-Targeted Small Molecule Drugs Consumption Value by Country (2020-2031)
6.3.2 United States RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe RNA-Targeted Small Molecule Drugs Consumption Value by Type (2020-2031)
7.2 Europe RNA-Targeted Small Molecule Drugs Consumption Value by Application (2020-2031)
7.3 Europe RNA-Targeted Small Molecule Drugs 麻豆原创 Size by Country
7.3.1 Europe RNA-Targeted Small Molecule Drugs Consumption Value by Country (2020-2031)
7.3.2 Germany RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific RNA-Targeted Small Molecule Drugs Consumption Value by Type (2020-2031)
8.2 Asia-Pacific RNA-Targeted Small Molecule Drugs Consumption Value by Application (2020-2031)
8.3 Asia-Pacific RNA-Targeted Small Molecule Drugs 麻豆原创 Size by Region
8.3.1 Asia-Pacific RNA-Targeted Small Molecule Drugs Consumption Value by Region (2020-2031)
8.3.2 China RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America RNA-Targeted Small Molecule Drugs Consumption Value by Type (2020-2031)
9.2 South America RNA-Targeted Small Molecule Drugs Consumption Value by Application (2020-2031)
9.3 South America RNA-Targeted Small Molecule Drugs 麻豆原创 Size by Country
9.3.1 South America RNA-Targeted Small Molecule Drugs Consumption Value by Country (2020-2031)
9.3.2 Brazil RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa RNA-Targeted Small Molecule Drugs Consumption Value by Type (2020-2031)
10.2 Middle East & Africa RNA-Targeted Small Molecule Drugs Consumption Value by Application (2020-2031)
10.3 Middle East & Africa RNA-Targeted Small Molecule Drugs 麻豆原创 Size by Country
10.3.1 Middle East & Africa RNA-Targeted Small Molecule Drugs Consumption Value by Country (2020-2031)
10.3.2 Turkey RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE RNA-Targeted Small Molecule Drugs 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 RNA-Targeted Small Molecule Drugs 麻豆原创 Drivers
11.2 RNA-Targeted Small Molecule Drugs 麻豆原创 Restraints
11.3 RNA-Targeted Small Molecule Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 RNA-Targeted Small Molecule Drugs Industry Chain
12.2 RNA-Targeted Small Molecule Drugs Upstream Analysis
12.3 RNA-Targeted Small Molecule Drugs Midstream Analysis
12.4 RNA-Targeted Small Molecule Drugs Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Roche
Novartis
PTC Therapeutics
Biogen
Accent Therapeutics
Anima Biotech
Arrakis Pharmaceuticals
Epics Therapeutics
Expansion Therapeutics
Gotham Therapeutics
H3 Biomedicine
Ribometrix
Skyhawk Therapeutics
STORM Therapeutics
Twentyeight-Seven Therapeutics
听
听
*If Applicable.